Poxviral vaccines

Patent metadata

Field	Value
Publication number	US-11278614-B2
Application number	US-202016782268-A
Country	US
Kind code	B2
Filing date	Feb 5, 2020
Priority date	Mar 15, 2013
Publication date	Mar 22, 2022
Grant date	Mar 22, 2022

Abstract

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.

First claim

The invention claimed is:

1. A Modified Vaccinia Ankara virus comprising a nucleic acid construct for use in priming or boosting an immune response, the nucleic acid construct comprising:
(i) a nucleic acid sequence encoding at least one antigenic protein or antigenic fragment thereof operatively linked to
(ii) a nucleic acid encoding at least one invariant chain.

2. The Modified Vaccinia Ankara virus according to claim 1 , wherein the at least one encoded invariant chain is of mammalian origin.

3. The Modified Vaccinia Ankara virus according to claim 1 , wherein the encoded at least one invariant chain is characterized by at least one of the following features:
(i) the endogenous KEY-region is deleted or substituted by a different sequence;
(ii) the methionine in positions 107 and 115 (human invariant chain) or in positions 90 and 98 (murine invariant chain) or the positions corresponding thereto in another invariant chain is substituted by another amino acid;
(iii) at least one sorting peptide is added to, removed from or replaces the endogenous sorting peptide of the invariant chain, and/or
(iv) at least one CLIP region is added to, removed from or replaces the endogenous CLIP region of the least one invariant chain.

4. The Modified Vaccinia Ankara virus according to claim 1 , wherein the encoded at least one invariant chain is a fragment of SEQ ID NO: 1 or SEQ ID NO: 3 of at least 40 consecutive amino acids or has at least 85% sequence identity to the same fragment of SEQ ID NO: 1 or SEQ ID NO:3.

5. The Modified Vaccinia Ankara virus according to claim 1 , wherein the at least one antigenic protein is a protein of a pathogenic organism.

6. The Modified Vaccinia Ankara virus according to claim 5 , wherein the pathogenic organism is a virus, a bacterium, a protist or a multicellular parasite.

7. The Modified Vaccinia Ankara virus according to claim 1 , wherein the invariant chain is selected from p35 or a variant or fragment thereof.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Colloca Stefano
• Cortese Riccardo
• Folgori Antonella
• Nicosia Alfredo

Classifications

• A61K39/00 Primary

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K14/70539

  MHC-molecules, e.g. HLA-molecules · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K14/005

  from viruses · CPC title

• C12N2710/24143

  viral genome or elements thereof as genetic vector · CPC title